



Epilepsy Pharmacogenomics: delivering biomarkers for clinical use

The work leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement n°279062.

SAVE THE DATE!

Epilepsy Pharmacogenomics: delivering biomarkers for clinical use (EpiPGX)

A free, open symposium showcasing data from the largest ever study of genomic predictors of treatment outcome in epilepsy

Institute of Education, University College London, UK

9.30 to 17.00, Wednesday 14th October 2015

Precision medicine is the key recent conceptual development in the clinical management of the epilepsies. Both disease causation genetics and pharmacogenomics will contribute to the aim of administering the right drug at the right dose to each individual with epilepsy. Over the last four years, the multicentre EpiPGX Consortium (www.epipgx.eu), funded through the European Union's FP7 programme, has explored response genomics for antiepileptic drugs.

This free-to-attend symposium will highlight recent outcomes plus work in progress from EpiPGX and will feature presentations from all of the key EpiPGX investigators. In addition, several prominent guest lecturers – including Sameer Zuberi, David Henshall, and Saskia Biskup – will set EpiPGX data in the wider context of epilepsy genomics, epigenomics and genetic diagnostics.

A full programme for the symposium will be available shortly.

Places at this event are limited, so please fill in the registration form at <http://www.epipgx.eu/registry-open-workshop> to reserve your place now. There is no registration fee and there are a limited number of modest travel bursaries available, subject to demand, for younger investigators (<40 years). Please ask for more details when you register your interest.

This promises to be a land-mark symposium and we look forward to your participation.

UCL Institute of Education: <http://www.ioe.ac.uk/>

Click here for [directions](#) and [travel advice](#).